Advanced Biomed Inc. ( (ADVB) ) has shared an update.
On March 5, 2025, Advanced Biomed Inc. entered into an underwriting agreement for its initial public offering (IPO) of 1,640,000 shares of common stock at $4.00 per share, which closed on March 7, 2025. The shares commenced trading on the Nasdaq Capital Market under the ticker symbol ‘ADVB’ on March 6, 2025. The IPO is expected to generate gross proceeds of $6.56 million, which will be used for clinical research, marketing, sales, and general working capital. This move marks a significant step in Advanced Biomed’s expansion strategy, potentially enhancing its market presence and operational capabilities.
More about Advanced Biomed Inc.
Advanced Biomed Inc. is a biotechnology company focused on the integration of interdisciplinary technologies to provide rapid and affordable assay products and services for cancer patients. The company has developed a microfluidic technology platform and offers a range of innovative devices and biochips for early screening, detection, diagnosis, staging, and treatment of cancer. Based in Taiwan, Advanced Biomed is expanding into China and preparing to establish operation centers in North America and Europe.
Average Trading Volume: 652,117
For a thorough assessment of ADVB stock, go to TipRanks’ Stock Analysis page.